A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer

Oncology

Volumn 77, Issue 5, 2009, Pages 300-303

  Nakai, Yousuke ^a   Isayama, Hiroyuki ^a   Sasaki, Takashi ^a   Sasahira, Naoki ^a   Ito, Yukiko ^a   Kogure, Hirofumi ^a   Togawa, Osamu ^a   Matsubara, Saburo ^a   Arizumi, Toshihiko ^a   Yagioka, Hiroshi ^a   Yashima, Yoko ^a   Kawakubo, Kazumichi ^a   Mizuno, Suguru ^a   Yamamoto, Keisuke ^a   Hirano, Kenji ^a   Tsujino, Takeshi ^a   Ijichi, Hideaki ^a   Toda, Nobuo ^a   Tada, Minoru ^a   Kawabe, Takao ^a   Omata, Masao ^a   more..

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Chemotherapy; Gemcitabine; Pancreatic cancer; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERPIGMENTATION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PILOT STUDY; PRIORITY JOURNAL; RASH; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-19-9 ANTIGEN; DEOXYCYTIDINE; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; PANCREATIC NEOPLASMS; PILOT PROJECTS; TEGAFUR;

EID: 70449652535     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000259616     Document Type: Article

References (16)

1. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413.
2. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Kohne CH, Mingrone W, Stemmer SM, Tamas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the central European Cooperative Oncology Group. J Clin Oncol 2007; 25: 2212-2217. (Pubitemid 46954645)
3. Heinemann V, Labianca R, Hinke A, Louvet C: Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol 2007; 18: 1652-1659.
4. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C: An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 2005; 68: 171-178.
5. Okusaka T, Funakoshi A, Furuse J, Boku N, Yamao K, Ohkawa S, Saito H: A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 2008;61:615-621.
6. Nakamura K, Yamaguchi T, Ishihara T, Kobayashi A, Tadenuma H, Sudo K, Kato H, Saisho H: Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 2005; 92: 2134-2139.
7. Ueno H, Okusaka T, Ikeda M, Ishiguro Y, Morizane C, Matsubara J, Furuse J, Ishii H, Nagase M, Nakachi K: A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology 2005; 69: 421-427.
8. Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H, Saisho H: Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 2006; 94: 1575-1579.
9. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial e2297. J Clin Oncol 2002; 20: 3270-3275.
10. Di Costanzo F, Carlini P, Doni L, Massidda B, Mattioli R, Iop A, Barletta E, Moscetti L, Recchia F, Tralongo P, Gasperoni S: Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian Oncology Group for Clinical Research (GOIRC). Br J Cancer 2005; 93: 185-189.
11. Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D: CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 2005; 93: 740-743.
12. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA: Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 2005; 93: 195-199.
13. Saad ED, Machado MC, Wajsbrot D, Abramoff R, Hoff PM, Tabacof J, Katz A, Simon SD, Gansl RC: Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer 2002; 32: 35-41.
14. Halm U, Schumann T, Schiefke I, Witzigmann H, Mossner J, Keim V: Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 2000; 82: 1013-1016.
15. Nakai Y, Kawabe T, Isayama H, Sasaki T, Yagioka H, Yashima Y, Kogure H, Arizumi T, Togawa O, Ito Y, Matsubara S, Hirano K, Sasahira N, Tsujino T, Tada M, Omata M: CA 19-9 response as an early indicator of the effectiveness of gemcitabine in patients with advanced pancreatic cancer. Oncology 2008; 75: 120-126.
16. Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, Bajetta E, Saletti P, Figer A, Scheithauer W, Herrmann R: CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 2008; 9: 132-138.